A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: Low response in patients previously treated with medroxyprogesterone

Pierre Alberto, Bernadette Mermillod, Eli Kaplan, Aron Goldhirsch, Jean Pierre Obrecht, Felix Jungi, Georg Martz, Laurent Barrelet, Franco Cavalli

Research output: Contribution to journalArticlepeer-review

Abstract

In an attempt to define the influence of prior hormonal treatments upon aminoglutethimide activity in advanced cancer of the breast, 42 heavily pretreated postmenopausal patients received aminoglutethimide, 4 × 250 mg daily, with hydrocortisone or cortisone. Twenty-six received high doses of medroxyprogesterone before entering this study. There was no significant difference in patients' characteristics with or without medroxyprogesterone pretreatment. A comparison of patients with and without prior medroxyprogesterone shows a significant difference in the response rate to aminoglutethimide-hydrocortisone (4 vs 32%, P = 0.02). In patients pretreated with tamoxifen but not with medroxyprogesterone the response rate to aminoglutethimide was 36%. These results suggest that aminoglutethimide has a low activity in breast cancer patients previously exposed to medroxyprogesterone, an agent with glucocorticoid-like activity inducing adrenal suppression.

Original languageEnglish
Pages (from-to)423-428
Number of pages6
JournalEuropean Journal of Cancer and Clinical Oncology
Volume21
Issue number4
DOIs
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: Low response in patients previously treated with medroxyprogesterone'. Together they form a unique fingerprint.

Cite this